Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors with an increasing incidence worldwide. Apolipoprotein M (apoM) is a novel apolipoprotein that is mainly expressed in liver and kidney tissues. However, the anti-tumor properties of apoM remain largely unknown. We evaluated the anti-tumor activities and mechanisms of apoM in HCC both in vivo and in vitro. Bioinformatic analysis and luciferase reporter assay results showed that apoM was a potential target of hsa-miR-573 and was downregulated after transfection with hsa-miR-573 mimics. Overexpression of apoM suppressed migration, invasion, and proliferation of hepatoma cells in vitro. Overexpression of hsa-miR-573 in hepatoma cells reduced apoM expression, leading to promotion of the invasion, migration, and proliferation of hepatoma cells in vitro. In addition, hsa-miR-573 markedly promoted growth of xenograft tumors in nude mice with an accompanying reduction in cell apoptosis. ApoM markedly inhibited growth of xenograft tumors in nude mice and promoted cell apoptosis. Moreover, Bcl2A1 mRNA and protein levels were inhibited by apoM overexpression and an increase in apoptosis rate by apoM was markedly compensated by Bcl2A1 overexpression in HepG2 cells. These results provide evidence that hsa-miR-573 promoted tumor growth by inhibition of hepatocyte apoptosis and this pro-tumor effect might be mediated through Bcl2A1 in an apoM-dependent manner. Therefore, our findings may be useful to improve understanding of the critical effects of hsa-miR-573 and apoM in HCC pathogenesis.
References
Lai CL, Yuen MF (2013) Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 57:399–408
Herszenyi L, Tulassay Z (2010) Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 14:249–258
Jemal A, Bray F, Center MM, Ferlay J, Ward E et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM (2013) Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 144:512–527
Livraghi T, Makisalo H, Line PD (2011) Treatment options in hepatocellular carcinoma today. Scand J Surg 100:22–29
Llovet JM, Schwartz M, Mazzaferro V (2005) Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 25:181–200
Dash S, Haque S, Joshi V, Prabhu R, Hazari S et al (2005) HCV-hepatocellular carcinoma: new findings and hope for effective treatment. Microsc Res Tech 68:130–148
Liu L, Miao R, Yang H, Lu X, Zhao Y et al (2012) Prognostic factors after liver resection for hepatocellular carcinoma: a single-center experience from China. Am J Surg 203:741–750
Jiang J, Nilsson-Ehle P, Xu N (2006) Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis 5:4
Jiang JT, Xu N, Zhang XY, Wu CP (2007) Lipids changes in liver cancer. J Zhejiang Univ Sci B 8:398–409
Uccello M, Malaguarnera G, Pelligra EM, Biondi A, Basile F et al (2011) Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma. Indian J Med Paediatr Oncol 32:71–75
Jiang J, Nilsson-Ehle P, Xu N (2006) Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis 5:4
Jiang JT, Wu CP, Xu N, Zhang XG (2009) Mechanisms and significance of lipoprotein(a) in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 8:25–28
Xu N, Dahlback B (1999) A novel human apolipoprotein (apoM). J Biol Chem 274:31286–31290
Zhang XY, Jiao GQ, Hurtig M, Dong X, Zheng L et al (2004) Expression pattern of apolipoprotein M during mouse and human embryogenesis. Acta Histochem 106:123–128
Jiang J, Wu C, Luo G, Zheng L, Chen L et al (2011) Expression of apolipoprotein M in human hepatocellular carcinoma tissues. Acta Histochem 113:53–57
Jin Q, Marsh J, Cornetta K, Alkhatib G (2008) Resistance to human immunodeficiency virus type 1 (HIV-1) generated by lentivirus vector-mediated delivery of the CCR5{Delta}32 gene despite detectable expression of the HIV-1 co-receptors. J Gen Virol 89:2611–2621
Hu YW, Zheng L, Wang Q, Zhong TY, Yu X et al (2012) Vascular endothelial growth factor downregulates apolipoprotein M expression by inhibiting Foxa2 in a Nur77-dependent manner. Rejuvenation Res 15:423–434
Shrivastava S, Petrone J, Steele R, Lauer GM, Di Bisceglie AM et al (2013) Up-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression. Hepatology 58:863–871
Fabbri M, Calin GA (2010) Epigenetics and miRNAs in human cancer. Adv Genet 70:87–99
Wang XW, Heegaard NH, Orum H (2012) MicroRNAs in liver disease. Gastroenterology 142:1431–1443
Zhao JY, Hu YW, Li SF, Hu YR, Ma X et al (2014) Dihydrocapsaicin down-regulates apoM expression through inhibiting Foxa2 expression and enhancing LXRalpha expression in HepG2 cells. Lipids Health Dis 13:50
Mu QF, Luo GH, Chen LJ, Wei J, Zheng L et al (2012) Apolipoprotein M expression in human colorectal cancer tissues and its clinicopathological relevance. Zhonghua Wei Chang Wai Ke Za Zhi 15:855–858
Vogler M (2012) BCL2A1: the underdog in the BCL2 family. Cell Death Differ 19:67–74
Haq R, Yokoyama S, Hawryluk EB, Jonsson GB, Frederick DT et al (2013) BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci USA 110:4321–4326
Vogler M (2012) BCL2A1: the underdog in the BCL2 family. Cell Death Differ 19:67–74
Ma X, Hu YW, Zhao ZL, Zheng L, Qiu YR et al (2013) Anti-inflammatory effects of propofol are mediated by apolipoprotein M in a hepatocyte nuclear factor-1 alpha-dependent manner. Arch Biochem Biophys 533:1–10
Hu YW, Zheng L, Wang Q (2010) Characteristics of apolipoprotein M and its relation to atherosclerosis and diabetes. Biochim Biophys Acta 1801:100–105
Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297
Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857–866
Gao P, Wong CC, Tung EK, Lee JM, Wong CM et al (2011) Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J Hepatol 54:1177–1184
Yip WK, Cheng AS, Zhu R, Lung RW, Tsang DP et al (2011) Carboxyl-terminal truncated HBx regulates a distinct microRNA transcription program in hepatocellular carcinoma development. PLoS One 6:e22888
Faber K, Axler O, Dahlback B, Nielsen LB (2004) Characterization of apoM in normal and genetically modified mice. J Lipid Res 45:1272–1278
Gu JG, Zhu CL, Cheng DZ, Xie Y, Liu F et al (2011) Enchanced levels of apolipoprotein M during HBV infection feedback suppresses HBV replication. Lipids Health Dis 10:154
Acknowledgments
This work was supported by grants from the National Natural Sciences Foundation of China (Nos.: 81301489 and 81271905) and the President Foundation of Nanfang Hospital, Southern Medical University.
Author contributions
Study design: YWH, QW, and LZ; sample collection: YWH, RYQ, ZPC, XMH, JYZ, JLH, XM, SFL, and XJW; experimentation: YWH, RYQ, ZPC, XMH, JYZ, JLH, XM, SFL,YHS, JJG, YCW, and XJW; data analysis: YWH and QW; and manuscript preparation: YWH, XMH, and JYZ. All of the authors read and approved the final version of this manuscript.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no competing interest associated with this report.
Rights and permissions
About this article
Cite this article
Hu, YW., Chen, ZP., Hu, XM. et al. The miR-573/apoM/Bcl2A1-dependent signal transduction pathway is essential for hepatocyte apoptosis and hepatocarcinogenesis. Apoptosis 20, 1321–1337 (2015). https://doi.org/10.1007/s10495-015-1153-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10495-015-1153-x